Water is a critical molecule for human life, and, because it is abundant in space, it also plays an important role in the life of […]

The post Astronomers appraise the amount of water in the Orion Nebula appeared first on Smithsonian Insider.

A newly described species of toothed whale that lived some 3-4 million years ago during the Pliocene, is causing scientists to reconsider what is known about its living cold-water relatives: narwhals and belugas.

The post New fossil whale species raises mystery regarding why narwhals and belugas live only in cold water appeared first on Smithsonian Insider.

Tom Crouch, Senior curator in the National Air and Space Museum's Aeronautics Division, discusses Thaddeus Lowe and the birth of American aerial reconnaissance during the Civil War. This presentation was recorded on May 11, 2011 on the National Mall.

The post Tom Crouch, Senior curator in the National Air and Space Museum’s Aeronautics Division, discusses Thaddeus Lowe and the birth of American aerial reconnaissance appeared first on Smithsonian Insider.

When two red panda babies are born in critical condition at Smithsonian’s National Zoo, caretakers make the crucial decision to raise them by hand.

The post Raising red pandas by hand at the National Zoo appeared first on Smithsonian Insider.

A joint research initiative carried out by scientists from the Smithsonian Institution, Saint Louis University and the Universidad de Los Andes in Venezuela, has resulted in […]

The post New daisy species discovered in Venezuela appeared first on Smithsonian Insider.

Source: Streetwise Reports   05/06/2020

Biopharmaceutical company Horizon Therapeutics Inc. (HZNP:NASDAQ), which focuses on developing and commercializing medicines for treatment of rare and rheumatic diseases, today announced its Q1/20 financial results for the period ending March 31, 2020. The firm began by advising that it is raising its FY/20 net sales guidance and revised its adjusted EBITDA guidance.

For Q1/20 the company reported that net sales increased by 27% to $355.9 million over Q1/19. The firm provided a breakdown of revenue by business unit and listed that in Q1/20 compared with Q1/19, its Orphan segment net sales increased 47% to $245.4 Million, KRYSTEXXA® net sales rose by 78% to $93.3 million and TEPEZZA (teprotumumab-trbw) net sales were $23.5 million, which exceeded expectations.

The firm advised that it is increasing FY/20 net sales guidance to $1.40-1.45 billion driven primarily by significantly higher TEPEZZA net sales and reflecting anticipated impacts from COVID-19. The company also presented revised FY/20 adjusted EBITDA guidance of $450-500 million, which reflects increased TEPEZZA program investment to support higher-than-expected demand.

The firm indicated that in Q1/20 it posted a GAAP net loss of $13.6 million with adjusted EBITDA of $107.2 million and non-GAAP net income of $83.2 million.

The company's Chairman, President and CEO Timothy Walbert commented, "We had a very strong start to 2020, highlighted by the early approval and rapid uptake of TEPEZZA, which significantly exceeded expectations, excellent KRYSTEXXA growth and our recent acquisition of HZN-825...We are increasing our full-year net sales guidance to account for significantly higher TEPEZZA net sales that more than offset the expected impact from COVID-19 this year, and we are widening both our net sales and adjusted EBITDA guidance ranges to account for future uncertainty. The fundamentals of our business are strong, including a robust cash position, and we continue to be very well positioned for the long term."

The company noted that it received FDA approval for TEPEZZA for the treatment of thyroid eye disease (TED) earlier this year in January. The firm described TED as "a rare, serious, progressive and vision-threatening autoimmune disease, and is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain and facial disfigurement." The company further s explained that "TEPEZZA, a fully human monoclonal antibody insulin-like growth factor-1 receptor (IGF-1R) inhibitor, is the first and only FDA-approved medicine for the treatment of TED."

Horizon Therapeutics is a biopharmaceutical company headquartered in Dublin, Ireland. The firm researches, develops and commercializes medicines for treatment of rare and rheumatic diseases.

Horizon has a market capitalization of around $7.1 billion with approximately 190.2 million shares outstanding and a short interest of about 4.9%. HZNP shares opened 10% higher today at $44.19 (+$3.81, +10.19%) over yesterday's $37.38 closing price and reached a new 52-week high price this morning of $43.57. The stock has traded today between $40.00 and $43.90 per share and is currently trading at $42.95 (+$5.57, +14.90%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Despite being used for several decades, test-based incentives have not consistently generated positive effects on student achievement, says a new report from the National Research Council.

Increasing the minimum age of legal access (MLA) to tobacco products will prevent or delay initiation of tobacco use by adolescents and young adults, particularly those ages 15 to 17, and improve the health of Americans across the lifespan, says a new report from the Institute of Medicine.

; Credit: /Jackie Ferrentino for NPR

A lot is at stake for students taking Advanced Placement exams, even in normal times. If you score high enough, you can earn college credit. It's also a big factor in college applications. But for some students, the idea of studying right now feels impossible.

"I'm constantly thinking about making sure my family doesn't get sick and I don't get sick," says Elise, a high school junior outside Boston. (We're not using her full name because she's worried about hurting her college applications.)

Concerns about the coronavirus have put most standardized tests, such as the SAT and ACT, on hold this spring. But AP exams are going forward with a new online format — and that's raising questions about fairness.

Elise, 17, says she spent months preparing for what is typically a three-hour, multiple-choice and essay-based exam; she was blindsided when she learned it will now be an online, 45-minute, open-response test.

"I have no idea what I'm going to get when I open that test," she says.

Elise was hoping the College Board, which administers AP exams, would cancel this year's exams, as it did the spring SATs. But since the tests are being offered, she says she feels she has to take them. She worries it would look bad on her college applications if she opted out.

For other students, just the idea of taking the exam at home is causing anxiety. Kayleen Guzman, 17, from Boston says it's hard to find peace and quiet in her house right now.

"Currently, it's me, my mom, my dog, my sister and my stepdad," she explains. "Sometimes I feel like it's too much chaos."

But Guzman is glad she still has the opportunity to take the AP exams at all this year. She says she worked hard in her two AP classes and she wants the chance to earn college credit.

However, it's still unclear how much credit colleges will give students for this year's exams.

"None of us would say that we are confident that a 3 or 4 or 5 on the AP exam this year means the exact same thing as a 3, 4 and 5 on the exam last year," says Harvard University's Andrew Ho, who studies the reliability of educational tests.

Ho says that because of the new format, this year's AP exams won't be measuring the same thing as previous years' exams. For one, the new tests will cover less material. And changing where kids take it — from a proctored classroom to their laptops at home — is a big deal. But Ho adds, "Just because it's not completely comparable doesn't mean the College Board and colleges, through their own policies, couldn't adjust."

Some colleges are already adjusting. The University of California system has come out explicitly to say it won't change the way it credits AP scores. Other colleges that didn't want to go on the record say they are planning to change their policies, but the details weren't ready to share just yet.

In a statement, College Board spokesperson Jerome White said the organization decided to move forward with AP testing to give motivated students the opportunity to earn college credit. He added that the organization is making "a significant financial investment" to make the exams available online, from cheating prevention software to helping students who may not have an Internet connection or access to a computer.

Still, some educators worry that those efforts won't be enough.

"This situation has created a lot of distraction," says Savannah Lodge-Scharff, an AP Physics teacher for Boston Public Schools. She argues that without in-person classes, many students won't be able to engage with the material in the same way. On top of that, financial stress means many of her students are juggling additional responsibilities, like taking care of siblings.

"I have some of my students who are working 40, 50, 60 hours a week at the grocery store right now in the fear their parents are going to be laid off," she explains.

And then there's the question of geographic equity. This year's exams will be administered at the same time worldwide, meaning students in Hong Kong will be up at midnight to take it.

This content is from Southern California Public Radio. View the original story at SCPR.org.

In this file photo, California Gov. Jerry Brown speaks during a news conference on January 17, 2014 in San Francisco, California. Brown on Thursday signed a bill that more than triples the state's annual tax credit for film and TV production to $330 million.; Credit: Justin Sullivan/Getty Images

Gov. Jerry Brown has headed to the cradle of the Hollywood film industry to sign legislation that more than triples the state's annual tax credit to $330 million a year for films and TV shows produced in California.

Brown says the increase is needed to help prevent other states and countries from hijacking film and TV production by offering their own lucrative incentives.

Brown signed the bill Thursday at the former Grauman's Chinese Theatre, where handprints and footprints of stars from the eras of Humphrey Bogart to Robert De Niro are embedded in concrete.

Under the new system, credit will be awarded based on the number of jobs a production creates and its overall positive impact on the state.

The historic cinema is now called the TCL Chinese Theatre IMAX.

Film tax credit doc

Source: Streetwise Reports   04/23/2020

Global healthcare packaging components manufacturer company West Pharmaceutical Services Inc. (WST:NYSE) today announced financial results for its first quarter ending March 31, 2020 and provided updated full-year 2020 financial guidance.

The company reported that net sales in Q1/20 increased to $491.5 million, a 10.8% increase from $443.5 million in Q1/19. During the same corresponding period, the firm stated that non-GAAP diluted earnings per share (EPS) increased by 36% to $0.99 and non-GAAP adjusted-diluted EPS increased by 36% to $1.01.

West Pharmaceutical Services advised that it is maintaining its FY/20 net sales guidance, which is expected to be in a range of $1.95-1.97 billion. The company stated that it is updating FY/20 adjusted-diluted EPS guidance to a new range of $3.52-3.62, compared to the prior estimated range of $3.45-3.55.

The company's President and CEO Eric M. Green commented, "During these unprecedented times, our priorities are focused on the well-being and safety of our team members as well as ensuring the supply of critical, high-quality components and solutions to our customers...I am extremely pleased that we delivered a strong performance in the first quarter given the challenging environment that the COVID-19 pandemic has had on our customers, our suppliers and our team members. In particular, we continued to deliver strong sales growth in high-value products, as demand trends from our worldwide customer base were similar to trends we saw last year. Our teams are partnering with a broad range of customers working to support efforts to develop solutions that address the global COVID-19 pandemic such as diagnostics, anti-viral therapeutics and vaccines."

The firm outlined sales in the most recent quarter by product line. The company reported that in Q1/20, net sales in its Proprietary Products segment grew by 9.7% to $373.5 million and that this segment "saw good demand for Westar^®, Daikyo^®, NovaPure^® and FluroTec^® components as well as for devices such as Daikyo Crystal Zenith^® syringes and cartridges and our self-injection platforms."

The firm noted that net sales from its Contract-Manufactured Products segment grew by 14.5% to $118.1 million led by sales of components for diagnostic devices and drug-injection delivery devices.

The company added that the Biologics market unit enjoyed double-digit organic sales growth, the Generics market unit achieved high-single digit organic sales growth and the Pharma market unit registered mid-single digit organic sales growth.

The firm additionally noted that during Q1/20 under its share repurchase program, it repurchased 761,500 shares for $115.5 million at an average share price of $151.65.

West Pharmaceutical Services is headquartered in Exton, Pa., roughly 35 miles west of Philadelphia, and is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems.

West Pharmaceutical has market capitalization of around $13.5 billion with approximately 73.84 million shares outstanding. WST shares opened 5.25% higher today at $179.05 (+$8.93, +5.25%) over yesterday's $170.12 closing price and reached a new 52-week high price this morning of $190.27. The stock has traded today between $177.13 and $190.27 per share and is currently trading at $187.04 (+$17.17, +10.11%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: WST:NYSE, )

Source: Streetwise Reports   05/06/2020

Biopharmaceutical company Horizon Therapeutics Inc. (HZNP:NASDAQ), which focuses on developing and commercializing medicines for treatment of rare and rheumatic diseases, today announced its Q1/20 financial results for the period ending March 31, 2020. The firm began by advising that it is raising its FY/20 net sales guidance and revised its adjusted EBITDA guidance.

For Q1/20 the company reported that net sales increased by 27% to $355.9 million over Q1/19. The firm provided a breakdown of revenue by business unit and listed that in Q1/20 compared with Q1/19, its Orphan segment net sales increased 47% to $245.4 Million, KRYSTEXXA® net sales rose by 78% to $93.3 million and TEPEZZA (teprotumumab-trbw) net sales were $23.5 million, which exceeded expectations.

The firm advised that it is increasing FY/20 net sales guidance to $1.40-1.45 billion driven primarily by significantly higher TEPEZZA net sales and reflecting anticipated impacts from COVID-19. The company also presented revised FY/20 adjusted EBITDA guidance of $450-500 million, which reflects increased TEPEZZA program investment to support higher-than-expected demand.

The firm indicated that in Q1/20 it posted a GAAP net loss of $13.6 million with adjusted EBITDA of $107.2 million and non-GAAP net income of $83.2 million.

The company's Chairman, President and CEO Timothy Walbert commented, "We had a very strong start to 2020, highlighted by the early approval and rapid uptake of TEPEZZA, which significantly exceeded expectations, excellent KRYSTEXXA growth and our recent acquisition of HZN-825...We are increasing our full-year net sales guidance to account for significantly higher TEPEZZA net sales that more than offset the expected impact from COVID-19 this year, and we are widening both our net sales and adjusted EBITDA guidance ranges to account for future uncertainty. The fundamentals of our business are strong, including a robust cash position, and we continue to be very well positioned for the long term."

The company noted that it received FDA approval for TEPEZZA for the treatment of thyroid eye disease (TED) earlier this year in January. The firm described TED as "a rare, serious, progressive and vision-threatening autoimmune disease, and is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain and facial disfigurement." The company further s explained that "TEPEZZA, a fully human monoclonal antibody insulin-like growth factor-1 receptor (IGF-1R) inhibitor, is the first and only FDA-approved medicine for the treatment of TED."

Horizon Therapeutics is a biopharmaceutical company headquartered in Dublin, Ireland. The firm researches, develops and commercializes medicines for treatment of rare and rheumatic diseases.

Horizon has a market capitalization of around $7.1 billion with approximately 190.2 million shares outstanding and a short interest of about 4.9%. HZNP shares opened 10% higher today at $44.19 (+$3.81, +10.19%) over yesterday's $37.38 closing price and reached a new 52-week high price this morning of $43.57. The stock has traded today between $40.00 and $43.90 per share and is currently trading at $42.95 (+$5.57, +14.90%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Soils play a vital role in the Earth's life-support system, yet their importance and value to society is not always recognised. A recent study suggests that incorporating soils into a National Capital and Ecosystem Services framework will raise the profile of soils and enable soils to be more easily integrated into policy decisions.

Our beliefs about how farm animals are raised can shape our meat-eating experience, according to a new study led by Lisa Feldman Barrett, University Distinguished Professor of Psychology at Northeastern University.

read more

The application roped in qualified doctors and medical professionals to furnish authentic corona-related information and bust myths around the same.

The company said it will utilise the capital to work with manufacturers to build IoT products for the consumer segment that can be plugged into its platform.

A new study has raised safety concerns over PFO4DA, a substance increasingly used as a substitute for PFOA, a harmful persistent organic pollutant (POP), in plastic production. PFO4DA was found to cause liver damage to mice in lab tests, and is also an environmental pollutant. The researchers caution that it may not be a suitable alternative to PFOA.

High blood pressure is linked to long-term exposure to traffic-related air pollution, new research suggests. After accounting for lifestyle factors, socioeconomic status and pre-existing health conditions, the researchers found that a rise in traffic emissions of nitrogen dioxide corresponded to a rise in blood pressure of exposed individuals.

A co-ordinated medical intervention that saw a distressed Jessica Marais rushed to a Sydney hospital by ambulance last weekend raises an important question: what can be done when repeat rehab fails?

Following on from a hugely successful first year of touring, live music experience Rock For Heroes is returning next month.

Former Watford head coach Javi Gracia has signed up to support Woking with a fundraising initiative by paying to put his name on the non-league club's shirt next season.

 
 000
 NOUS42 KNHC 311430
 REPRPD
 WEATHER RECONNAISSANCE FLIGHTS
 CARCAH, NATIONAL HURRICANE CENTER, MIAMI, FL.
 1030 AM EDT TUE 31 MARCH 2020
 SUBJECT: WINTER STORM PLAN OF THE DAY (WSPOD)
          VALID 01/1100Z TO 02/1100Z APRIL 2020
          WSPOD NUMBER.....19-122
 
 I.  ATLANTIC REQUIREMENTS
     1. NEGATIVE RECONNAISSANCE REQUIREMENTS.
     2. OUTLOOK FOR SUCCEEDING DAY.....NEGATIVE.
 
 NOTE:  THIS IS THE LAST WSPOD OF THE SEASON UNLESS CONDITIONS
        DICTATE OTHERWISE.
 
 $$
 WJM
 
 NNNN
 

Saudi Arabia is now indicating it's determined to do whatever it takes to support an oil price recovery.

How we as a community can help to support the parents and celebrate the beauty of special needs children.

California group gets riled when officials bury a dead sea lion near their volleyball court.

An infographic makes the argument for the USDA to get involved with setting national standards for the snacks allowed to be sold in schools.

Raising a child in a mentally stimulating environment has been linked to developing a smaller brain cortex, which in turn is linked to higher IQ.

All of the ingredients for this monochromatic side dish are in season in most regions right now, and they combine to make a quick and healthy side dish.

Actor and environmentalist says President stood up to Big Oil by delaying project and calling for more environmental reviews.

Will Minnesota's most mystique-filled home go the way of Graceland?

The 2017 Beaujolais Nouveau has just been released, fulfilling the destiny of many French gamay grapes.

Working with the nonprofit Solar Aid, students earn enough to bring electric light to a school in Kenya

The reason red meat is linked to higher cancer risk is that it contains a sugar molecule called Neu5Gc that isn't naturally found in the human body.

Private groups are shaping business plans to tap into the resource-rich environs of outer space. Early celestial targets with commercial cross hairs on them are

Raising campaign funds is a difficult balancing act for the Louisiana governor.

Nancy Rabalais has spent a lifetime documenting the effect of ocean "dead zones." The Louisiana researcher has increased our understanding of these hypoxic zone

Scientists propose dropping poison to kill mice on the Farallon Islands, but there's concern that wildlife and water quality will suffer.

Break out the whisky and the haggis for this celebration of Scotland's national poet, Robert Burns.

Organic supermarket chain EkoPlaza teams with an anti-plastic waste group to launch a supermarket aisle liberated from plastic packaging.

Consumer Reports’ risk guide helps shoppers make informed decisions when buying fruits and vegetables.

A Silicon Valley investor with a penchant for green technology raised $1 billion for a new venture fund. His vision: science experiments and clean technologies

Jimmy Fallon is joined by Ladysmith Black Mambazo as they sing an ode to Fair Trade and Ben & Jerry's.

Environmental advocates worry that proposed titanium mining could permanently impact the Okefenokee Swamp.